Product ID |
Product Name |
CAS# |
Purity |
Y3297453 |
tert-Butyl (S)-3-(piperidin-3-yl)azetidine-1-carboxylate |
2174940-66-8 |
95% |
Y3293509 |
(R)-2-((R)-3-Amino-3-(4-((2-methylquinolin-4-yl)methoxy)phenyl)-2-oxopyrrolidin-1-yl)-N-hydroxy-4-methylpentanamide formate |
2922280-85-9 |
95% |
Y3119061 |
5,5'-(Piperazine-2,5-diyl)bis(2-hydroxybenzamide) |
2517940-02-0 |
95%+ |
Y3297079 |
N-Cyclohexyltetradecanamide |
17427-95-1 |
95% |
Y3306865 |
BRD4-BD1-IN-2 |
2761321-26-8 |
99% |
Y3291977 |
JAK-IN-21 |
2445499-20-5 |
99% |
Y3286503 |
TAM470 |
1802498-63-0 |
98% |
Y3305124 |
JNJ-65355394 |
2230598-99-7 |
100% |
Y3289189 |
p53 Activator 3 |
2636839-90-0 |
95% |
Y3307906 |
a-Glucosidase-IN-23 |
161187-57-1 |
99% |
Y3304755 |
Antiviral agent |
380458-45-7 |
99% |
Y3309082 |
Pirmitegravir |
2245231-10-9 |
99% |
Y3294128 |
DKI5 |
1101130-96-4 |
98% |
Y3306677 |
a-Amylase-IN-1 |
148404-10-8 |
99% |
Y3309236 |
CJ-13,610 hydrochloride |
179420-27-0 |
99% |
Y3307103 |
AChE/BChE/MAO-B-IN-1 |
2416910-82-0 |
99% |
Y3305341 |
DP-1 hydrochloride |
1472616-35-5 |
99% |
Y3306909 |
G43 |
690693-02-8 |
99% |
Y3309156 |
a-Cyclopentyl-4-(2-quinolinylmethoxy)benzeneacetic acid |
128253-12-3 |
97% |
Y3308121 |
(1S,2R)-Globalagliatin |
2514278-46-5 |
99% |
Y3307723 |
(S)-PF-03716556 |
928774-44-1 |
99% |
Y3295444 |
Calcium Channel antagonist 2 |
874370-15-7 |
98% |
Y3309833 |
ZINC12409120 |
1010888-06-8 |
98% |
Y3305929 |
3-(9-Chloro-3-methyl-4-oxoisoxazolo[4,3-c]quinolin-5(4H)-yl)-N-(3,4,5-trimethoxyphenyl)benzeneacetamide |
246238-55-1 |
99% |
Y3286446 |
2-[4-methyl-3-(trifluoromethyl)phenyl]oxirane |
2228389-16-8 |
95% |
Y3309234 |
COX-2-IN-34 |
2788578-71-0 |
98% |
Y3307562 |
(Iso)-Samixogrel |
133276-52-5 |
98% |
Y3311927 |
(+)-OSU 6162 |
160777-43-5 |
99% |
Y3306092 |
Fosopamine(HCl) |
135962-35-5 |
100% |
Y3307115 |
MK-0686 |
1159193-97-1 |
99% |
Y3311796 |
Enerisant HCl |
1152749-07-9 |
99% |
Y3309303 |
Azepexole hydrochloride |
147663-20-5 |
98% |
Y3307942 |
(3aR,9aR)-Fluparoxan |
105182-47-6 |
100% |
Y3304561 |
(S, R)-LSN 3318839 |
2765539-92-0 |
99% |
Y3309071 |
(-)-Vorozole |
132042-69-4 |
99% |
Y3311885 |
Serba-2 |
533884-08-1 |
100% |
Y3311601 |
CP-866087 |
519052-04-1 |
100% |
Y3307665 |
PU-H71 HCl |
2095432-24-7 |
95% |
Y3307454 |
Z26395438 |
2803-63-6 |
99% |
Y3308344 |
N-((4,6-dimethyl-2-oxo-1,2-dihydropyridin-3-yl)methyl)-5-(N-ethylcyclopropanecarboxamido)-4-methyl-4'-morpholino-[1,1'-biphenyl]-3-carboxamide |
2238820-26-1 |
98% |
Y3311742 |
GSK-3 inhibitor 4 |
2227279-83-4 |
98% |
Y3310955 |
CDK-IN-10 |
660822-84-4 |
97% |
Y3311701 |
DSS30 |
883027-32-5 |
99% |
Y3310537 |
LEM-14-1189 |
2987501-17-5 |
97% |
Y3310367 |
MAK-683 hydrochloride |
2170606-94-5 |
98% |
Y3308185 |
1-(4-chloro-3-(trifluoromethyl)phenyl)-3-(7-(1-methyl-1H-pyrazol-4-yl)-2,3,4,9-tetrahydro-1H-carbazol-3-yl)urea |
2379727-88-3 |
97% |
Y3288711 |
icFSP1 |
1115910-36-5 |
99% |
Y3288293 |
M3541 |
1360628-91-6 |
99% |
Y3305301 |
LSD1-IN-27 |
2904571-94-2 |
98% |
Y3305843 |
SFI003 |
2361332-90-1 |
99% |
Y3307457 |
N-((4-([1,2,4]triazolo[1,5-a]pyridin-6-yl)-5-(6-methylpyridin-2-yl)-1H-imidazol-2-yl)methyl)-2-bromoaniline |
1352608-94-6 |
99% |
Y3310216 |
WAY-270250 |
852367-46-5 |
99% |
Y3295759 |
Nimucitinib |
2740557-24-6 |
99% |
Y3305472 |
H-PRO-HIS-CYS-LYS-ARG-MET-OH acetate |
2918771-43-2 |
99% |
Y3310297 |
RR-src acetate |
2986315-28-8 |
97% |
Y3304576 |
2-(2-chloro-5-nitrophenyl)propan-2-ol |
1936288-94-6 |
95% |
Y3297292 |
1-(chloromethyl)-3-(methoxymethyl)benzene |
119858-82-1 |
95% |
Y3307678 |
5-(but-3-yn-1-yl)-2-chloropyridine |
2228624-00-6 |
95% |
Y3304804 |
tert-Butyl (2-(2-chloro-4-nitrophenethoxy)ethyl)(methyl)carbamate |
2722698-00-0 |
95% |
Y3311500 |
Lomedeucitinib |
2328068-29-5 |
99% |
Y3305812 |
3-(1-Methyl-4-pyrazolyl)phenylboronic Acid |
1373043-37-8 |
95% |
Y3308762 |
3-Methyl-5-(1-methyl-4-pyrazolyl)phenylboronic Acid |
1373043-40-3 |
95% |
Y3311835 |
3-[1-(2-Methoxyethyl)-4-pyrazolyl]phenylboronic Acid |
1373043-50-5 |
95% |
Y3308923 |
Mirabegron Impurity 2 |
2762802-66-2 |
95% |
Y3316306 |
(E)-1-(Chloromethyl)-4-(2-nitrovinyl)benzene |
1440549-00-7 |
95% |
Y3310035 |
2-(2-Amino-4-thiazolyl)acetyl Chloride Hydrochloride |
66313-72-2 |
95% |
Y3315593 |
3-[(1,1-Dimethylethyl)dithio]-1-propanol |
144868-32-6 |
98% |
Y3305949 |
Kallikrein 5-IN-2 |
2361160-57-6 |
98% |
Y3295133 |
1-methyl-3-(trifluoromethyl)-1H-pyrazole-4-sulfonic acid |
2969040-01-3 |
95% |
Y3291265 |
2,5-dichloro-N-(2-(isopentylamino)-2-oxoethyl)benzamide |
2872629-73-5 |
95% |
Y3294143 |
tert-butyl 16-hydroxyhexadecanoate |
2708281-44-9 |
95% |
Y3305246 |
ND-011992 |
2446880-46-0 |
99% |
Y3287750 |
9,9'-(2-Bromo-1,3-phenylene)bis(9H-carbazole) |
2227146-17-8 |
95% |
Y3290003 |
Phosphatidylcholine transfer protein inhibitor-2 |
379712-59-1 |
98% |
Y3311190 |
(SP-4-1)-[1,3-Bis[2,6-bis(1-propylbutyl)phenyl]-1,3-dihydro-2H-imidazol-2-ylidene]dichloro(3-chloropyridine-N)palladium |
2387503-86-6 |
95% |
Y3178664 |
(1S)-CCR2 antagonist 1 |
1683534-97-5 |
98% |
Y3176895 |
Val-Ala-PABC-Exatecan trifluoroacetate |
2928571-45-1 |
98% |
Y3180496 |
Basroparib |
1858179-75-5 |
98% |
Y3180494 |
PROTAC TTK degrader-1 |
2953426-43-0 |
95% |
Y3178813 |
SUCNR1-IN-1 |
2711753-52-3 |
99% |
Y3306829 |
Gymnemanol |
174324-52-8 |
98% |
Y3316766 |
Sitakisogenin |
53187-93-2 |
95% |
Y3313201 |
Marsglobiferin |
147395-99-1 |
95% |
Y3144874 |
LPA5 antagonist 1 |
2839471-45-1 |
98% |
Y3144880 |
NAAA-IN-1 |
1439366-66-1 |
99% |
Y3309490 |
(S)-Retosiban |
2994298-20-1 |
99% |
Y3306416 |
Ethyl 2-(2-methylcyclohexyl)acetate |
116530-83-7 |
95% |
Y3313839 |
(S)-3-(3-((((9H-Fluoren-9-yl)methoxy)carbonyl)amino)phenyl)-2-((tert-butoxycarbonyl)amino)propanoic acid |
170157-57-0 |
95% |
Y3118974 |
2-[3-(Trimethylammonio)propyl]isoquinolinium dibromide |
4353-42-8 |
95%+ |
Y3287346 |
CK156 |
2910938-59-7 |
99% |
Y3305303 |
Nrf2-IN-3 |
6325-13-9 |
99% |
Y3287933 |
CIDD-0149897 |
2862784-20-9 |
99% |
Y3292677 |
cis-Indatraline hydrochloride |
86939-08-4 |
99% |
Y3305707 |
SLC26A3-IN-1 |
307552-53-0 |
98% |
Y3309434 |
SMO-IN-2 |
1822355-27-0 |
95% |
Y3304708 |
InhA-IN-4 |
894309-72-9 |
100% |
Y3308771 |
BTK-IN-16 |
2883232-92-4 |
99% |
Y3306884 |
HIV-1 inhibitor-54 |
2771211-71-1 |
97% |
Y3289836 |
LNP Lipid-3 |
2648693-32-5 |
95% |
Y3286513 |
CDK7-IN-21 |
2766124-39-2 |
95% |